A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 39/385 (2006.01) C07K 14/47 (2006.01) C07K 14/78 (2006.01) C12N 9/68 (2006.01)
Patent
CA 2487291
A novel fusion protein, comprising a receptor-antagonizing domain and an angiogensis inhibiting domain, characterized, for example, by its ability to block apoptosis and/or inhibit endocrine response, is useful in treating cancer. For example, a human prolactin antagonist-endostatin fusion protein combines apoptosis induction and angiogenesis inhibition to combat cancer.
La présente invention porte sur une nouvelle protéine hybride comprenant un domaine d'antagonisme de récepteur et un domaine d'inhibition de l'angiogenèse. La protéine de cette invention, qui se caractérise par exemple par son aptitude à bloquer l'apoptose et/ou à inhiber la réponse endocrinienne, est utilisée dans le traitement du cancer. Par exemple, une protéine hybride comprenant l'endostatine et un antagoniste de la prolactine humaine combine l'induction de l'apoptose et l'inhibition de l'angiogenèse en vue de lutter contre le cancer.
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Ghc Research Development Corporation
Greenville Hospital System
LandOfFree
Human prolactin antagonist-angiogenesis inhibitor fusion... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human prolactin antagonist-angiogenesis inhibitor fusion..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human prolactin antagonist-angiogenesis inhibitor fusion... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1393788